Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylscopolamine bromide
Drug ID BADD_D01437
Description A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
Indications and Usage Used as adjunctive therapy for the treatment of peptic ulcer. Also used to treat nausea and vomiting due to motion sickness.
Marketing Status Not Available
ATC Code A03BB03; S01FA03
DrugBank ID DB00462
KEGG ID D01976
MeSH ID D019832
PubChem ID 23724781
TTD Drug ID Not Available
NDC Product Code 51927-0047; 43063-740; 51991-191; 55742-014; 43063-741; 51991-192; 76385-101; 51886-0301; 76385-100
Synonyms N-Methylscopolamine | N Methylscopolamine | Methscopolamine | N-Methylscine Methylsulfate | Methylsulfate, N-Methylscine | N Methylscine Methylsulfate | N-Methylscopolamine Bromide | Bromide, N-Methylscopolamine | N Methylscopolamine Bromide | Hyoscine Methobromide | Methobromide, Hyoscine | Scopolamine Methylbromide | Methylbromide, Scopolamine | N-Methylscopolamine Iodide | Iodide, N-Methylscopolamine | N Methylscopolamine Iodide | Hyoscine Methiodide | Methiodide, Hyoscine | N-Methylscopolamine Methylsulfate | Methylsulfate, N-Methylscopolamine | N Methylscopolamine Methylsulfate | Methylscopolammonium Methylsulfate | Methylsulfate, Methylscopolammonium | N-Methylscopolamine Nitrate | N Methylscopolamine Nitrate | Nitrate, N-Methylscopolamine | Methylscopolamine Nitrate | Nitrate, Methylscopolamine | Skopyl | Ulix | DD-234 | DD 234 | DD234 | N-Methylscopolamine Methylchloride | Methylchloride, N-Methylscopolamine | N Methylscopolamine Methylchloride
Chemical Information
Molecular Formula C18H24BrNO4
CAS Registry Number 155-41-9
SMILES C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C.[Br-]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Accommodation disorder06.02.04.001--Not Available
Ageusia17.02.07.001; 07.14.03.003--Not Available
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Asthenia08.01.01.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Cycloplegia17.17.02.003; 06.05.03.002--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.003--
Dry mouth07.06.01.002--
Feeling abnormal08.01.09.014--Not Available
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Hypohidrosis23.02.03.005; 08.01.03.029--
Insomnia19.02.01.002; 17.15.03.002--
Intraocular pressure increased13.07.04.002--Not Available
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Palpitations02.01.02.003--
Somnolence19.02.05.003; 17.02.04.006--
Suppressed lactation21.05.02.003; 18.06.02.001--Not Available
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Urinary hesitation20.02.02.009--Not Available
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.001--
Vision blurred17.17.01.010; 06.02.06.007--
The 1th Page    1 2    Next   Last    Total 2 Pages